The COVID-19 pandemic has transformed the way we work, and the biotech industry is no exception. As the world recovers, companies are navigating a new landscape of changes in HR, office and lab space, and real estate. To help you understand and prepare for these changes, the Biotechnology Innovation Organization (BIO) convened this webinar, The New Normal: Post-COVID Workforce and Office Trends.

In this webinar, we cover:

--The changing biotech real estate market, rise of innovation districts, and what it means for your company

--How HR policies have evolved in response to the pandemic, including remote work and employee support programs

--Evolving workforce talent demands Changes in office and lab space design to ensure employee safety and productivity

Cell + Gene Therapy Science Series

An ASGCT collaboration with BIO and FDA

The Cell and Gene Therapy (CGT) Science Series is a quarterly seminar series focused on scientific topics related to cell and gene therapy products. The CGT Science Series is intended to foster scientific exchange between the Biotechnology Innovation Organization (BIO), American Society of Gene & Cell Therapy (ASGCT), and FDA's Center for Biologics Evaluation and Research (CBER) review staff on a variety of topics that span the CGT product lifecycle. The seminars are planned as 60-minute virtual webinars featuring a speaker from one of the three organizations. The CGT Science Series will enable a deep dive into a specific technical and/or scientific area.  Topics in the series may include, but are not limited to, nonclinical, CMC, clinical, or post-market phases of development related to CGT product lifecycle. 

Short and Long Read Sequencing for AAV Characterization

The inaugural CGT Science Series seminar  focused on NGS characterization of AAV and was presented by Dr. Lauriel Earley. 

Dr. Earley is a Senior Scientist with Shape Therapeutics who has been studying the basic biology of adeno-associated virus for over decade. During her graduate studies at Oregon Health & Science University, she examined the role of assembly-activating protein under the mentorship of Dr. Hiroyuki Nakai. After receiving her PhD, she joined Dr. Jude Samulski's laboratory at the University of North Carolina, Chapel Hill and took on a project to characterize the intrinsic promoter ability of the inverted terminal repeat sequences from various AAV serotypes. Dr. Earley joined Shape Therapeutics in 2019 and is currently leading their vector platform development team. In addition, Dr. Earley has been an active member of ASGCT since 2012 and is currently serving on the Patient Outreach Committee.

This is the first meeting in a series of conferences cohosted by the Biotechnology Innovation Organization (BIO) and Solve M.E. that are designed to foster a private-public engagement and create an R&D roadmap for diagnostics and treatments for Long COVID and Post-infection Diseases.

Objective: Convene stakeholders to advance R&D to diagnose and treat Long COVID and post-infection diseases to:

--Increase awareness among drug developers to the unmet need and business opportunity in these indications

--Establish a knowledge base of emerging research in Long COVID and existing body of data in other post-infection diseases (such as dysautonomia, myalgic encephalomyelitis/ chronic fatigue syndrome, mast cell activation, and others).

--Highlight potential biological targets for therapeutic and preventative approaches

--Engage experts and regulators to inform design of clinical studies

--Establish a pre-competitive collaborative network

Recorded on February 21, 2023. Part 1 of 3.

This is the first meeting in a series of conferences cohosted by the Biotechnology Innovation Organization (BIO) and Solve M.E. that are designed to foster a private-public engagement and create an R&D roadmap for diagnostics and treatments for Long COVID and Post-infection Diseases.

Objective: Convene stakeholders to advance R&D to diagnose and treat Long COVID and post-infection diseases to:

--Increase awareness among drug developers to the unmet need and business opportunity in these indications

--Establish a knowledge base of emerging research in Long COVID and existing body of data in other post-infection diseases (such as dysautonomia, myalgic encephalomyelitis/ chronic fatigue syndrome, mast cell activation, and others).

--Highlight potential biological targets for therapeutic and preventative approaches

--Engage experts and regulators to inform design of clinical studies

--Establish a pre-competitive collaborative network

Recorded on February 21, 2023. Part 2 of 3.

This is the first meeting in a series of conferences cohosted by the Biotechnology Innovation Organization (BIO) and Solve M.E. that are designed to foster a private-public engagement and create an R&D roadmap for diagnostics and treatments for Long COVID and Post-infection Diseases.

Objective: Convene stakeholders to advance R&D to diagnose and treat Long COVID and post-infection diseases to:

--Increase awareness among drug developers to the unmet need and business opportunity in these indications

--Establish a knowledge base of emerging research in Long COVID and existing body of data in other post-infection diseases (such as dysautonomia, myalgic encephalomyelitis/ chronic fatigue syndrome, mast cell activation, and others).

--Highlight potential biological targets for therapeutic and preventative approaches

--Engage experts and regulators to inform design of clinical studies

--Establish a pre-competitive collaborative network

Recorded on February 21, 2023. Part 3 of 3.

Looking for an efficient and effective way to source new partnerships and manage your meetings for JPM Week 2023? View this webinar to learn more about how BIO One-on-One Partnering™ can help. Learn about BIO’s onsite meeting space in San Francisco, how to schedule your meetings with different location options, and a get a first look at the system’s newest feature – optional meeting participants. Also get a sneak peek at how you can stay in-the-know about networking and other opportunities during JPM week.

For more information and to register for BIO Partnering at JPM 2023, please visit: https://www.bio.org/events/bio-partnering-jpm/registration.

• Preview of BIO’s onsite meeting space in San Francisco 
• Partnering best practices & how to schedule your meetings
• Live demo of the system’s latest feature – optional meeting participants
• Sneak peak of BIO and Novateur Ventures’ JPM Week Events Guide mobile app
• Q&A with the host

As an emerging life sciences company, you are overseeing talented personnel and working on multiple projects all while managing overhead costs and staying up-to-date on the industry. The Biotechnology Innovation Organization (BIO) is here to make all of that a little easier and through your membership you receive access to benefits that will save you time and money, and stay current on all things happening in our industry.

This webinar details how your company can take full advantage of your BIO membership investment via the BIO Business Solutions cost savings program.

In 2021, the United States government launched multiple international initiatives focused on issues at the intersection of climate, agriculture, and sustainable food systems. These initiatives are housed under the U.S. Department of Agriculture (USDA) and involve a cross section of government and non-governmental partners.

As part of the 2021 UN Food Systems Summit, the United States launched a Coalition for Sustainable Productivity Growth for Food Security and Resource Conservation (the SPG Coalition) with a goal to accelerate the transition to more sustainable food systems through productivity growth that optimizes agricultural sustainability across social, economic, and environmental dimensions.

Agriculture Innovation Mission for Climate (AIM for Climate/AIM4C) is an initiative launched at COP 26 and led by the United Arab Emirates and the United States. AIM for Climate is focused on addressing climate change and global hunger by increasing investment in, and other support for, climate-smart agriculture and food systems innovation over five years (2021–2025) and enabling greater public-private and cross-sectoral partnerships.

This webinar hosted by the Biotechnology Innovation Organization (BIO) provides an update on the status of the initiatives including a look ahead to COP 27 and beyond. In addition, USDA staff helping to lead this work discuss ways for private sector partners to engage in, support, and amplify the work of the SPG Coalition and AIM for Climate.

On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, which includes a number of significant prescription drug-related provisions, including a new drug price negotiation program in Medicare, inflation rebates in Medicare Part B and Part D, and a redesign of the Medicare Part D benefit, with a new patient out-of-pocket cap of $2,000.

Leaders from the Biotechnology Innovation Organization (BIO) as well as experts from the Hogan Lovells Life Sciences & Health Care team provide detailed overviews with Q&A on these newly enacted provisions.

The webinar covers the new drug price negotiation program, inflation rebates in Medicare, the Medicare Part D benefit redesign, and new out-of-pocket cap, as well as other important provisions that will reduce patient cost sharing.

• Introduction and Context [0:00:00–0:03:53]:
  John Murphy, Chief Policy Officer, BIO
• Inflation Reduction Act Background [0:03:54–0:07:26]:
  Crystal Kuntz, VP Health Policy and Research, BIO
• Drug Price Negotiation Program [0:07:27–0:44:07]:
  Ken Choe, Partner, Hogan Lovells
• Medicare Part B and Part D Inflation Rebates [0:44:08–1:18:29]:
  Alice Valder Curran, Partner, Hogan Lovells
• Medicare Part D Redesign [1:18:30–1:53:05]:
  Melissa Bianchi, Partner, Hogan Lovells
• Conclusion and Next Steps [1:53:06–1:58:02]:
  John Murphy, Chief Policy Officer, BIO Downloadable webinar slides at https://bit.ly/BIO-IRA-slides